Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
Analytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisEureka AI Inside
Professional Services
Customer Stories
Blog
Global Innovation Report
Glossary
Newsroom
Webinars & Training
Frontier
User Community
Trust and Security
PatentBench
LLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report STT-MRAM reaches commercial inflection in 2026: embedded vs. standalone tradeoffs, endurance-retention physics, patent hotspots, and market projections to $7.9B.
Updated on April 13, 2026 | Written by PatSnap Team A novelty search in patent law is a structured investigation …
Continue reading "What Is a Patent Novelty Search? AI Changes 2026"
Updated on April 13, 2026 | Written by PatSnap Team AI drug discovery depends on three distinct categories of data …
Continue reading "AI Drug Discovery Data: Patents, Biosequences & Structures"
Updated on April 13, 2026 | Written by PatSnap Team Patent claim parsing is the process of decomposing a patent …
Continue reading "How Patent Claim Parsing Works in AI IP Analysis"
Updated on April 13, 2026 | Written by PatSnap Team Discover which patent API includes biosequence and chemical structure data …
Continue reading "Patent API with Biosequence & Chemical Data 2026"
Updated on April 10, 2026 | Written by PatSnap Team Building an AI-powered freedom-to-operate (FTO) analysis tool requires more than …
Continue reading "Best Patent Data API for FTO Analysis 2026"
Updated on April 10, 2026 | Written by PatSnap Team If you’re building AI workflows in Cursor or Claude Desktop …
Continue reading "MCP Server for Patent Data: Best Tools 2026"
Article | Report How RORγt inverse agonists (VTP-43742, ABBV-157) differ mechanistically from IL-23p19 antibodies in Th17 suppression — clinical tolerability, tissue pharmacodynamics, and patent evidence.
Article | Report How do oral small molecule IL-17A inhibitors compare to Bimekizumab? Explore the mechanistic rationale, patent landscape, and oral bioavailability solutions.
Article | Report Explore Applied Materials' semiconductor deposition, etch, and materials engineering technology roadmap from 2010 to 2026—key innovations, process trends, and future outlook.
Article | Report Silicon photonics vs. InP vs. thin-film LiNbO₃: a 2026 PIC technology landscape covering data center demand, performance benchmarks, and market growth.
Article | Report How satralizumab, sarilumab, and siltuximab differ in IL-6 pathway blockade, CNS penetrance, and patent-disclosed antibody engineering for half-life extension.
Article | Report MBCFET vs nanosheet vs forksheet: compare GAA transistor architectures, process integration challenges, and the 2026 competitive landscape from Samsung to TSMC.
Article | Report Telitacicept vs. Belimumab in IgA nephropathy and SLE: mechanistic rationale for dual APRIL/BAFF blockade and clinical evidence on IgA levels, proteinuria, and B-cell dynamics.
Article | Report How allosteric TYK2 pseudokinase inhibition achieves IL-12/IL-23/IFN-α selectivity while avoiding JAK1/2/3 hematopoietic and thromboembolic risks — clinical evidence in psoriasis and SLE.